Last reviewed · How we verify
FM+R
FM+R, developed by the University of Bologna, is a marketed small molecule with an unknown mechanism of action. The drug's key composition patent is set to expire in 2028, which may provide a period of market exclusivity. However, the lack of a defined mechanism of action poses a significant risk, potentially limiting its therapeutic applications and regulatory support.
At a glance
| Generic name | FM+R |
|---|---|
| Sponsor | University of Bologna |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The LungVision Navigational Platform for Preoperative Labeling of Pulmonary Ground Glass Nodules With Fiducial Markers (NA)
- Muscle Architecture and Muscle Strength in Fibromyalgia
- Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics (PHASE1)
- Correlation Between Clinical Measurement Scales for Gross Motor Function
- Risk Factors of Primary Fibromyalgia
- Use of Amplification in Children With Unilateral Hearing Loss (NA)
- Prophylaxis for Aspiration of Gastric Contents. (PHASE4)
- Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FM+R CI brief — competitive landscape report
- FM+R updates RSS · CI watch RSS
- University of Bologna portfolio CI